MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy

By Danish H Sayed, C. Hong, Ieng-Yi Chen, Jacqueline Lypowy, M. Abdellatif. Circulation Research, 2007

757 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6615d120362b86a38c9599baeab7322e96a823b3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

RNA silencing: Methods and protocols (2006, neutral): “Many of these microRNAs are present in the heart and dynamically regulate the response to acute cardiac stress and in some cases during long-term compensatory response of the heart to a chronic injury or hemodynamic overload [62, 63].”
Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure (2008, background): “It is intriguing that a single miRNA (miR-1) appears to be involved in the regulation of diverse cardiac and skeletal muscle function, including cellular proliferation, differentiation, cardiomyocyte hypertrophy, cardiac conduction, and arrhythmias (8, 10, 11, 26, 30).”
MicroRNA-133 controls cardiac hypertrophy (2007, result): “This model is in line with in vitro functional studies on miR-1 reported by other”
Altered microRNA expression in human heart disease. (2007, background): “miR-1 was recently reported to be downregulated in four different murine models of cardiac hypertrophy or failure (4, 15), consistent with our finding of miR-1 downregulation in AS and DCM.”
Mechanistic Pathways of Sex Differences in Cardiovascular Disease. (2017, background): “The expression of several 100s different miRNAs has been described in the mouse heart, many of which are regulated during the development of LV hypertrophy (53, 70, 346, 378, 390, 401).”
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, background): “illustrated the importance of miRNAs in the NS by the finding that 70% of known miRNAs are expressed in the brain [287].”
Non-coding RNAs in disease: from mechanisms to therapeutics (2023, neutral): “…particularly human cancers, such as by functioning as oncogenes and/or tumour suppressors 8 . miRNAs have also been found to be differentially expressed in a range of other human pathologies, including cardiovascular diseases (CVDs) 9,10 , neurological diseases 6,7 and infectious diseases 11 .”
MicroRNAs in development and disease. (2011, background): “miR-23a, which is clustered with miR-27a and miR-24, is also upregulated during pressure overload (102, 533, 600, 626) and isoproterenol-induced hypertrophy (370).”
The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 (2011, background): “A recent study using a miRNA microarray approach showed that miR-1 expression was downregulated in the setting of a mouse model of aortic constriction-induced cardiac hypertroph”